Loading...

Pulmatrix's Drug Has "Blockbuster" Potential CFO Bill Duke CFO of Pulmatrix (NASDAQ: PULM)

2,382 views

Loading...

Loading...

Transcript

The interactive transcript could not be loaded.

Loading...

Loading...

Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on May 17, 2017

http://Stock-Sector.com
In an Interview with Stock-Sector, Duke Explains How Pulmatrix's Innovative Technology is Targeting Major Unmet Medical Needs and has Potential to Bring the Company a Share of a $33 Billion Market

NEW YORK, NY / ACCESSWIRE / May 17, 2017 / Stock-Sector.com, an online source of news about promising medical, technology and energy companies, and CEOCFO Magazine, an independent investment publication that highlights important technologies and companies, today released an interview with William Duke, Jr., CFO of Pulmatrix, Inc., (PULM).

Pulmatrix, a clinical stage biopharmaceutical company, is developing an inhaled therapy for treating fungal infections in patients suffering from severe lung disease (PUR1900) that has "blockbuster" potential, Bill Duke told Stock-Sector.

Loading...

When autoplay is enabled, a suggested video will automatically play next.

Up next


to add this to Watch Later

Add to

Loading playlists...